Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Recruiting 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 3Colorectal Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Turcot syndrome 1Sarcoma 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Advanced Kidney Cancer 1

Interventions

Carboplatin 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2selinexor 1ponatinib 1poly ICLC 1pemigatinib 1neratinib 1donafenib 1cobimetinib 1ceritinib 1cemiplimab 1brigatinib 1abemaciclib 1Thymopentin 1Taxes 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Radiation 1Pluvicto 1Platinum Compounds 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Neck Dissection 1NF protocol 1Magnetic Resonance Spectroscopy 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma × Ipilimumab × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡